Lung NeoplasmsNCT07588347
Construction and Preliminary Evaluation of Dyadic Acceptance and Commitment Therapy for Couples With Fear of Lung Cancer Recurrence
A study testing Dyadic Acceptance and Commitment Therapy (ACT) for lung cancer patients and their spouse caregivers addressing FCR and routine care and routine care in people with Lung Neoplasms and Acceptance and Commitment Therapy, run by Feifei Huang.
Trial summary
The goal of this clinical trial is to develop a simple, scientific, effective, and culturally adapted dyadic Acceptance and Commitment Therapy (ACT) intervention program (the ADAPT program) targeting fear of cancer recurrence (FCR) among lung cancer patients and their spouse caregivers. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Lung Neoplasms, Acceptance and Commitment Therapy, Spouses
- What is being tested?
- Dyadic Acceptance and Commitment Therapy (ACT) for lung cancer patients and their spouse caregivers addressing FCR and routine care and routine care
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 72 participants
- Where
- No sites listed yet
- Study dates
- 15 May 2026to 30 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients:
- Diagnosis of primary lung cancer confirmed by pathological examination.
- Age ≥ 22 years for men and ≥ 20 years for women (legal marriage age in China).
- Have undergone lung cancer surgery and are scheduled to receive the first round of radiotherapy and/or chemotherapy treatment
- Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) score ≥ 13, indicating moderate-to-severe FCR.
- Eastern Cooperative Oncology Group (ECOG) ≤2.
Show all 13Show fewer
- Aware of their diagnosis and willing to participate voluntarily.
- Normal cognitive function (Montreal Cognitive Assessment [MoCA] score ≥ 26), alert and conscious, and able and willing to communicate their thoughts.
- Spouse Caregivers:
- Identified by the patient as the primary caregiver, providing ≥ 50% of care in the past 2 weeks.
- Legally married to the patient.
- Age ≥ 22 years for men and ≥ 20 years for women.
- Normal cognitive function (MoCA score ≥ 26), no diagnosed mental disorders, able to communicate effectively, and willing to share their thoughts.
Who cannot join
- Patients:
- Diagnosed mental disorders or currently receiving psychiatric treatment.
- Presence of personality disorders, intellectual disability, memory disorders, brain injury, or neurological disease.
- Concurrent malignant tumors in other organs.
- Severe complications (e.g., chest pain and/or dyspnea due to pleural tumor invasion).
- Spouse caregiver unwilling to participate.
Show all 12Show fewer
- History of upper limb fractures or surgery resulting in impaired hand function.
- Participation in other similar psychological interventions.
- Spouse Caregivers:
- Presence of serious comorbid conditions (e.g., respiratory failure, malignant tumors, or other critical illnesses).
- Patient unwilling to participate.
- Participation in other research studies.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this clinical trial is to develop a simple, scientific, effective, and culturally adapted dyadic Acceptance and Commitment Therapy (ACT) intervention program (the ADAPT program) targeting fear of cancer recurrence (FCR) among lung cancer patients and their spouse caregivers. The study will also evaluate the feasibility, acceptability, and preliminary effectiveness of the ADAPT program.
The main research questions are as follows:
Read more
- Is the ADAPT intervention program feasible and acceptable for lung cancer patients and their spouse caregivers?
- Compared with usual care, can the ADAPT intervention program preliminarily reduce FCR levels in both patients and their spouse caregivers? Can the program improve coping styles, illness perceptions, family functioning, and intimate relationships among both patients and their spouse caregivers? Can the program enhance psychological flexibility and quality of life (QOL) in both patients and their spouse caregivers? Researchers will compare the ADAPT intervention program with usual care to evaluate its preliminary effectiveness in reducing FCR among lung cancer patients and their spouse caregivers.
Participants will:
- Receive the ADAPT intervention twice during each radiotherapy and/or chemotherapy cycle, for a total of three treatment cycles (approximately 3 months);
- Complete questionnaires at baseline (before the intervention), immediately after the intervention, and one month post-intervention;
- Report outcomes including FCR severity, FCR triggers, psychological flexibility, illness perception, dyadic coping, family functioning, intimacy, and quality of life (QOL).
- Conditions
- Lung Neoplasms, Acceptance and Commitment Therapy, Spouses
- Being tested
- Dyadic Acceptance and Commitment Therapy (ACT) for lung cancer patients and their spouse caregivers addressing FCR and routine care, routine care
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dyadic Acceptance and Commitment Therapy (ACT) for lung cancer patients and their spouse caregivers addressing FCR and routine careOther
In addition to routine care provided to the control group, the ACT intervention will be delivered by researchers who have completed formal training in Acceptance and Commitment Therapy (ACT). The intervention will be conducted in a quiet and comfortable demonstration room within the department.
The intervention will be delivered in a face-to-face, couple-based format. It will consist of six sessions, with two sessions per treatment cycle, each lasting 35-75 minutes, over a total of three treatment cycles.
The intervention will incorporate techniques such as metaphor-based exercises, mindful breathing, body scan, the T-puzzle, and the Chinese finger trap.
The preliminary structure is as follows: six fixed in-person sessions (Sessions 1-6), supplemented by online homework assignments completed between sessions.
routine careOther
① Health education:
- Disease knowledge education
- Nutrition and hygiene education
- Follow-up management and symptom monitoring: Conduct a telephone follow-up within one month after the patient is discharged from the hospital to ensure timely monitoring of the patient's physical condition.
- Home rehabilitation management: Provide nutritional counseling services for the patient and spouse caregiver, guide home-based dietary adjustments, and maintain good nutritional status and immunity. Encourage the patient and spouse caregiver to communicate promptly with the medical team when experiencing uncomfortable symptoms, thereby speeding up recovery and improving rehabilitation outcomes.
| Study group | Role | What they receive |
|---|---|---|
| Control group | Active comparator | Not described Receives: Other: routine care |
| Intervention group | Experimental | Not described Receives: Other: Dyadic Acceptance and Commitment Therapy (ACT) for lung cancer patients and their spouse caregivers addressing FCR and routine care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in fear of cancer recurrence severity of lung cancer patients-The Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF)
The scale consists of 9 items, each rated from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 36, where 0 indicates no fear of cancer recurrence and 36 indicates the highest possible fear. A score of 13 or higher is defined as subclinical fear of cancer recurrence.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in fear of cancer recurrence severity of spouse caregivers-Fear of Cancer Recurrence Inventory Short Form-Caregiver Version (FCRI-SF-C)
The scale consists of 9 items, each rated from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 36, where 0 indicates no fear of cancer recurrence and 36 indicates the highest possible fear. A score of 13 or higher is defined as subclinical fear of cancer recurrence.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Secondary outcomes (14)
Change from baseline in fear of cancer recurrence triggering factors-The Fear of Cancer Recurrence Inventory-Triggering factors (FCRI-T)
This 8-item dimension assesses how often daily triggers elicit fear of cancer recurrence. Each item is scored from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 32, where 0 indicates that none of the factors trigger fear and 32 indicates that all factors always trigger fear.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in psychological flexibility-Comprehensive Assessment of ACT Processes (CompACT)
The CompACT contains 22 items, each scored from 0 to 6. Zero is equivalent to "never" and 6 indicates "always". After reverse-scoring the values and committed action domain (plus four items of the mindfulness and self-as-context domain), total scores range from 0 to 132, where 0 indicates the lowest possible psychological flexibility and 132 indicates the highest possible psychological flexibility.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in illness perception-Brief Illness Perception Questionnaire (B-IPQ)
The B-IPQ includes 8 items, each scored from 0 to 10. Zero is equivalent to "no perception of that aspect" and 10 indicates "extreme perception of that aspect". Total scores range from 0 to 80, where 0 indicates a very benign illness perception and 80 indicates the most threatening illness perception possible. The ninth open-ended item asks participants to list the three most important causal factors.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in dyadic coping-Dyadic Coping Inventory (DCI)
The DCI consists of 37 items, each rated from 1 to 5. One is equivalent to "very rarely" and 5 indicates "very frequently". Total scores range from 35 to 75, where 35 indicates the lowest possible dyadic coping competence and 75 indicates the highest possible dyadic coping competence.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in intimate relationship-Unidimensional Relationship Closeness Scale (URCS)
This 11-item scale uses a 5-point scale from 1 to 5. 1 is equivalent to "strongly disagree" and 5 indicates "strongly agree". The mean of all item scores is calculated, ranging from 1 to 5, where 1 indicates the lowest perceived closeness and 5 indicates the highest perceived closeness.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in family care-Family Adaptation, Partnership, Growth, Affection, Resolve index Questionnaire (Family APGAR Questionnaire)
The Family APGAR has 5 items, each scored from 0 to 2. Zero is equivalent to "hardly ever" and 2 indicates "almost always". Total scores range from 0 to 10, where 0 indicates the poorest family function and 10 indicates the best family function. Scores of 7-10 indicate good family function, 4-6 moderate dysfunction, and 0-3 severe dysfunction.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in quality of life of lung cancer patients-Functional Assessment of Cancer Therapy (FACT-L V4.0)
The FACT-L V4.0 consists of 36 items. Each item is scored from 0 to 4. Zero is equivalent to "not at all" and 4 indicates "very much". Positively worded items are scored 0-4; reverse-worded items are scored 4-0. The total score is the sum of five dimension scores (physical, social/family, emotional, functional, and lung-specific), ranging from 0 to 144, where 0 indicates the poorest possible quality of life and 144 indicates the best possible quality of life.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in quality of life of spouse caregivers-The 12-item short from healthy survey (SF-12)
The SF-12 includes 12 items covering eight dimensions. Items 1,8,9,10 are reverse-scored. Standardized scores for the PCS and MCS each range from 0 to 100, where 0 indicates the worst possible quality of life and 100 indicates the best possible quality of life.
Measured: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Recruitment Rate: Percentage of Eligible Participants Who Successfully Enroll in the Study Out of All Potentially Eligible Participants Meeting Inclusion/Exclusion Criteria
Recruitment rate is calculated as (number of eligible participants who successfully enroll in the study / total number of potentially eligible participants meeting all inclusion and none of the exclusion criteria) × 100%. The rate ranges from 0% to 100%, with a higher rate indicating better recruitment efficiency.
Measured: Post-intervention (3 months)
Consent Compliance Rate: Percentage of Participants Who Sign Informed Consent Among Those Who Meet Inclusion Criteria
Consent compliance rate is calculated as (number of participants who sign the informed consent form / total number of participants who meet the predefined inclusion criteria) × 100%. The rate ranges from 0% to 100%.
Measured: Post-intervention (3 months)
Participation Rate: Percentage of Randomized Participants Who Completed All Intervention Sessions
Participation rate is calculated as (number of participants who completed all intervention sessions / total number of participants randomized) × 100%. The rate ranges from 0% to 100%.
Measured: Post-intervention (3 months)
Withdrawal Rate: Percentage of Initially Enrolled Participants Who Voluntarily Withdraw or Are Lost to Follow-Up
Withdrawal rate is calculated as (number of participants who voluntarily withdraw from the study or are lost to follow-up after enrollment / total number of participants initially enrolled) × 100%. The rate ranges from 0% to 100%.
Measured: Post-intervention (3 months)
Number of Participants with Study-Related Adverse Events as Assessed by CTCAE v4.0
The study uses a self-developed Adverse Event Form to document study-related adverse events (AEs) occurring during the study period. The incidence rate is calculated as (number of participants experiencing at least one study-related AE / total number of enrolled participants) × 100%. Severity grading follows the CTCAE v4.0.
Measured: Intervene in the whole process (3 months)
Satisfaction with the Intervention Program as Assessed by Qualitative Interviews
Semi-structured interviews are conducted by the investigator using a final interview guide developed through group brainstorming and revised by a nursing professor experienced in qualitative research. Sampling continues until no new themes emerge and meaning saturation is achieved. Thematic analysis is used to identify satisfaction-related patterns, and findings are reported with representative quotes. No predefined numeric threshold is applied.
Measured: Post-intervention (3 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start15 May 2026 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 72 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Feifei Huang
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Feifei Huang, Fujian Medical University
- Investigators
- Feifei Huang, Ph. D, Study director, Fujian Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07588347
- Sponsor's protocol ID
- Ethical Review No. 2 (2026)
- Status last verified
- May 2026
- First submitted
- 4 May 2026
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The datasets are not publicly available due privacy reasons but are available from the director upon reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Construction and Preliminary Evaluation of Dyadic Acceptance and Commitment Therapy for Couples With Fear of Lung Cancer Recurrence
- ClinicalTrials.gov ID
- NCT07588347
- Acronym / sponsor ID
- Ethical Review No. 2 (2026)
- Conditions
- Lung Neoplasms, Acceptance and Commitment Therapy, Spouses
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- Feifei HuangUniversity, hospital or other
- Study start
- 15 May 2026 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to develop a simple, scientific, effective, and culturally adapted dyadic Acceptance and Commitment Therapy (ACT) intervention program (the ADAPT program) targeting fear of cancer recurrence (FCR) among lung cancer patients and their spouse caregivers. The study will also evaluate the feasibility, acceptability, and preliminary effectiveness of the ADAPT program.
The main research questions are as follows:
- Is the ADAPT intervention program feasible and acceptable for lung cancer patients and their spouse caregivers?
- Compared with usual care, can the ADAPT intervention program preliminarily reduce FCR levels in both patients and their spouse caregivers? Can the program improve coping styles, illness perceptions, family functioning, and intimate relationships among both patients and their spouse caregivers? Can the program enhance psychological flexibility and quality of life (QOL) in both patients and their spouse caregivers? Researchers will compare the ADAPT intervention program with usual care to evaluate its preliminary effectiveness in reducing FCR among lung cancer patients and their spouse caregivers.
Participants will:
- Receive the ADAPT intervention twice during each radiotherapy and/or chemotherapy cycle, for a total of three treatment cycles (approximately 3 months);
- Complete questionnaires at baseline (before the intervention), immediately after the intervention, and one month post-intervention;
- Report outcomes including FCR severity, FCR triggers, psychological flexibility, illness perception, dyadic coping, family functioning, intimacy, and quality of life (QOL).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control group | Active comparator | Other: routine care |
| Intervention group | Experimental | Other: Dyadic Acceptance and Commitment Therapy (ACT) for lung cancer patients and their spouse caregivers addressing FCR and routine care |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Diagnosis of primary lung cancer confirmed by pathological examination.
- Age ≥ 22 years for men and ≥ 20 years for women (legal marriage age in China).
- Have undergone lung cancer surgery and are scheduled to receive the first round of radiotherapy and/or chemotherapy treatment
- Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) score ≥ 13, indicating moderate-to-severe FCR.
- Eastern Cooperative Oncology Group (ECOG) ≤2.
Key exclusion criteria (12 listed)
- Diagnosed mental disorders or currently receiving psychiatric treatment.
- Presence of personality disorders, intellectual disability, memory disorders, brain injury, or neurological disease.
- Concurrent malignant tumors in other organs.
- Severe complications (e.g., chest pain and/or dyspnea due to pleural tumor invasion).
- Spouse caregiver unwilling to participate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dyadic Acceptance and Commitment Therapy (ACT) for lung cancer patients and their spouse caregivers addressing FCR and routine careIn addition to routine care provided to the control group, the ACT intervention will be delivered by researchers who have completed formal training in Acceptance and Commitment Therapy (ACT). The intervention will be conducted in a quiet and comfortable demonstration room within the department. The intervention will be delivered in a face-to-face, couple-based format. It will consist of six sessions, with two sessions per treatment cycle, each lasting 35-75 minutes, over a total of three treatment cycles. The intervention will incorporate techniques such as metaphor-based exercises, mindful breathing, body scan, the T-puzzle, and the Chinese finger trap. The preliminary structure is as follows: six fixed in-person sessions (Sessions 1-6), supplemented by online homework assignments completed between sessions. | Other | Intervention group |
| routine care① Health education: 1. Disease knowledge education 2. Nutrition and hygiene education * Follow-up management and symptom monitoring: Conduct a telephone follow-up within one month after the patient is discharged from the hospital to ensure timely monitoring of the patient's physical condition. * Home rehabilitation management: Provide nutritional counseling services for the patient and spouse caregiver, guide home-based dietary adjustments, and maintain good nutritional status and immunity. Encourage the patient and spouse caregiver to communicate promptly with the medical team when experiencing uncomfortable symptoms, thereby speeding up recovery and improving rehabilitation outcomes. | Other | Control group |
Primary outcome
Change from baseline in fear of cancer recurrence severity of lung cancer patients-The Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The scale consists of 9 items, each rated from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 36, where 0 indicates no fear of cancer recurrence and 36 indicates the highest possible fear. A score of 13 or higher is defined as subclinical fear of cancer recurrence.
Change from baseline in fear of cancer recurrence severity of spouse caregivers-Fear of Cancer Recurrence Inventory Short Form-Caregiver Version (FCRI-SF-C)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The scale consists of 9 items, each rated from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 36, where 0 indicates no fear of cancer recurrence and 36 indicates the highest possible fear. A score of 13 or higher is defined as subclinical fear of cancer recurrence.
14 secondary outcomes
Change from baseline in fear of cancer recurrence triggering factors-The Fear of Cancer Recurrence Inventory-Triggering factors (FCRI-T)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in psychological flexibility-Comprehensive Assessment of ACT Processes (CompACT)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in illness perception-Brief Illness Perception Questionnaire (B-IPQ)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in dyadic coping-Dyadic Coping Inventory (DCI)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in intimate relationship-Unidimensional Relationship Closeness Scale (URCS)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in family care-Family Adaptation, Partnership, Growth, Affection, Resolve index Questionnaire (Family APGAR Questionnaire)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in quality of life of lung cancer patients-Functional Assessment of Cancer Therapy (FACT-L V4.0)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in quality of life of spouse caregivers-The 12-item short from healthy survey (SF-12)
Time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Recruitment Rate: Percentage of Eligible Participants Who Successfully Enroll in the Study Out of All Potentially Eligible Participants Meeting Inclusion/Exclusion Criteria
Time frame: Post-intervention (3 months)
Consent Compliance Rate: Percentage of Participants Who Sign Informed Consent Among Those Who Meet Inclusion Criteria
Time frame: Post-intervention (3 months)
Participation Rate: Percentage of Randomized Participants Who Completed All Intervention Sessions
Time frame: Post-intervention (3 months)
Withdrawal Rate: Percentage of Initially Enrolled Participants Who Voluntarily Withdraw or Are Lost to Follow-Up
Time frame: Post-intervention (3 months)
Number of Participants with Study-Related Adverse Events as Assessed by CTCAE v4.0
Time frame: Intervene in the whole process (3 months)
Satisfaction with the Intervention Program as Assessed by Qualitative Interviews
Time frame: Post-intervention (3 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Individual participant dataSharing planned: No. The datasets are not publicly available due privacy reasons but are available from the director upon reasonable request.
Related trials for Lung Neoplasms
RecruitingObservational study
Evaluation for NCI Surgery Branch Clinical Research Protocols
Synovial Cell Cancer, Melanoma
RecruitingPhase 1/2
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 2
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Feifei Huang, Ph. D study director
Fujian Medical University
Questions about this trial
What is this clinical trial studying?
A study testing Dyadic Acceptance and Commitment Therapy (ACT) for lung cancer patients and their spouse caregivers addressing FCR and routine care and routine care in people with Lung Neoplasms and Acceptance and Commitment Therapy, run by Feifei Huang.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Feifei Huang, Ph. D (+86 13763869099, pt860315@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in fear of cancer recurrence severity of lung cancer patients-The Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) (time frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026; AzTrials last refreshed its copy on 27 Oct 2026.